How to Evaluate Any Company’s Cash Flow - 2 examples

 How to Systematically Evaluate Any Company’s Cash Flow

When you open a company’s cash flow statement:

1. Start with “Cash from Operations” trend – increasing or erratic?

2. Compare “Profit from Operations” vs. “CFO” – ideally CFO ≥ 80% of profit.

3. Look at Working Capital Changes – consistent negatives mean blocked cash.

4. Review Investing Cash Flow – negative = expansion, but ensure it’s not draining liquidity.

5. Check Financing Cash Flow – frequent borrowings/dividends indicate stress or dilution.

6. See Net Cash Flow trend – positive or consistently improving is ideal.

_____________

🧩 1. The Structure of a Cash Flow Statement

It has three key sections:

1. Cash Flow from Operating Activities (CFO):

   • Cash actually generated from the core business — selling goods, collecting receivables, paying suppliers, taxes, etc.

   • It reflects the health and sustainability of business operations.

2. Cash Flow from Investing Activities (CFI):

   • Cash spent or gained from buying/selling assets — property, machinery, investments, etc.

   • Negative CFI is often good if it reflects investment in capacity expansion.

3. Cash Flow from Financing Activities (CFF):

   • Cash movements related to capital — equity, loans, dividends, etc.

   • It shows how the company funds itself.

4. Net Cash Flow = CFO + CFI + CFF

   • Indicates how total cash changes year over year.

---

🔍 2. How to Read and Analyze (with Your Two Examples)

Ref ( expand 'cash from operating activities' )

Coral Lab https://www.screener.in/company/524506/

Par Drugs https://www.screener.in/company/PAR/

Let’s compare Coral Laboratories and Par Drugs in simple interpretation:

Aspect	Coral Laboratories	Par Drugs
Profit from Operations	Generally rising — ₹10.16 Cr (2014) → ₹30.23 Cr (2025). Good sign.	Also rising — ₹7.25 Cr → ₹20.51 Cr. Stable growth.
Cash from Operating Activity (CFO)	Highly volatile: e.g. -1 (2025), -5 (2024), +13 (2023), +6 (2022). Despite profits, poor cash conversion.	Relatively more stable CFO: 5→9→7→12→20→16 (2025). Indicates better profit-to-cash translation.
Working Capital Changes	Very negative (-24.12 Cr in 2025, -19.51 in 2024): receivables/inventory growing faster than payables. Cash stuck in operations.	Near neutral in 2025 (0.17 Cr). Controlled working capital — efficient operations.
Direct Taxes	Regular payments, but large fluctuations.	More stable, proportionate to profits.
CFI (Investing)	Mixed — some years -10, -6, etc. Likely capital expansion or machinery purchase.	Large negative (-25 in 2025): heavy investment phase (possibly new capacity).
CFF (Financing)	Minor movements, meaning company not relying heavily on debt.	Also low leverage; mostly self-funded.
Net Cash Flow	Often negative → -1 (2025), -5 (2024): weak liquidity due to poor working capital.	Slightly better pattern, though -9 (2025) due to capex — but prior years show positive cash generation.

---

🧠 3. Key Insights — Linking Cash Flow to Business Strength & Growth

A. Profitability vs. Cash Flow

• A company with high profit but poor CFO (like Coral Labs) may have earnings quality issues — profits may be tied up in receivables/inventory.

• Par Drugs converts profits to cash more efficiently — a sign of better operational discipline.

B. Working Capital Efficiency

• Coral’s large negative working capital changes indicate cash blockage — customers paying late or inventory piling up.

• Par’s near-zero working capital change shows tight control — an indicator of business stability.

C. Investment Activity (CFI)

• Sustained moderate negative CFI is healthy — it shows reinvestment in growth.

• A sudden large negative (like -25 in 2025 for Par Drugs) may mean aggressive capacity expansion — good if matched with future sales, risky if demand slows.

D. Financing Activity (CFF)

• Both companies show low dependency on external borrowing, meaning self-sustained growth.

• Stable or low CFF over time supports fundamental strength and low financial risk.

E. Net Cash Flow Trend

• For Coral Labs: Fluctuating and negative in recent years → may indicate stress in converting growth into liquidity.

• For Par Drugs: Generally positive or balanced → better liquidity management and resilience.

---

📊 4. Correlating Cash Flow to Growth Probability & Stability

Factor	Positive Indicators	Coral Labs	Par Drugs
Growth Potential	Profits + Reinvestment	High profit, some reinvestment (good growth potential but risky cash flow)	High profit + strong reinvestment (healthy growth base)
Fundamental Strength	Consistent CFO, low debt	Volatile CFO → weaker fundamentals	Consistent CFO + low debt → strong fundamentals
Stability / Liquidity	Steady cash flow & efficient WC	Poor WC → low liquidity stability	Efficient WC → high stability
Overall Outlook	-	Profit growth but cash stress → may face short-term liquidity pressure	Balanced growth → good candidate for steady compounding

---

1. <>

🧭 6. Summary (Your Case Study Insight)

Company	Core Insight
Coral Laboratories	Profitable but poor cash discipline — aggressive working capital, uneven cash flow. Needs improvement in collections and inventory control.
Par Drugs & Chemicals	Moderate profits but efficient cash management — better liquidity and growth quality. Larger recent investment hints at capacity expansion and medium-term growth opportunity.